|
|
Vol. 15.25 – 1 November, 2024
|
|
|
|
|
|
|
|
Scientists constitutively activated interleukin-6 cytokine family signal transducer (IL6ST) signaling in the prostate epithelium of a Pten-deficient prostate cancer mouse model in vivo and examined IL6ST expression in large cohorts of prostate cancer patients. [Molecular Cancer]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
The authors found that Siglec-7 and Siglec-9 were associated with poor prognosis in prostate cancer patients, and were highly expressed in myeloid cells, including macrophages, in prostate tumor tissues.
[Journal of Clinical Investigation]
|
|
|
|
|
|
Scientists showed that IMPA1-derived inositol enriched in prostate cancer stem cells (PCSC) was a key metabolite crucially maintaining PCSCs for CRPC progression and androgen ablation therapy resistance.
[Journal of Experimental Medicine]
|
|
|
|
|
|
Pathogenic or likely pathogenic germline variants in 26 DNA repair genes were assessed in relation to metastasis-free survival in high-risk, localized prostate cancer and to overall survival in metastatic castration-sensitive prostate cancer and metastatic CRPC.
[Clinical Cancer Research]
|
|
|
|
|
|
Investigators reported a regulatory mechanism of AKT kinase by zinc ions. Mechanistically, zinc ions directly bound to AKT and facilitated AKT activation through disrupting the interaction between PH and kinase domains within AKT molecule.
[Oncogene]
|
|
|
|
|
|
Although SLC7A11 could increase the migration ability of tumor cells, BAY-876 effectively suppressed the viability of prostate cancer cells, particularly those with high SLC7A11 expression.
[Biology Direct]
|
|
|
|
|
|
Using a unique transgenic mouse model that mimicked chronic non-bacterial prostatitis in men, researchers investigated the impact of inflammation on androgen receptor in basal prostate stem cells and their differentiation in vivo.
[Communications Biology]
|
|
|
|
|
|
This was a single-arm, head-to-head, prospective Phase II trial designed to enroll 102 men with prostate cancer who experienced biochemical progression during androgen deprivation therapy. [Scientific Reports]
|
|
|
|
|
|
|
|
Scientists discuss the various mechanisms by which the tumor microenvironment influences prostate cancer progression. The roles of different cells, cytokines, chemokines, and growth factors in modulating the immune response and prostate tumour growth are discussed.
[Journal of Drug Targeting]
|
|
|
|
|
|
The authors provide an overview of recent basic research in prostate cancer, focusing on two main areas: prostate cells and their tumor microenvironments. [International Journal of Urology]
|
|
|
|
|
|
|
|
The University of California, Los Angeles (UCLA) Urology department has been awarded $6 million from the California Department of Health Care Services to continue providing vital care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.
[UCLA Health]
|
|
|
|
|
|
Dr. Luca Valle at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), was awarded a $2.1 million grant from the US Department of Veterans Affairs (VA) to develop new methods to better understand biological factors that lead to prostate cancer coming back after radiation therapy. [UCLA Health]
|
|
|
|
|
|
ESSA Pharma, Inc. announced that it has made the decision to terminate the Phase II clinical trial evaluating masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic CRPC naïve to second-generation anti-androgens. [ESSA Pharma, Inc.]
|
|
|
|
|
|
|
|
December 11 – 13, 2024 Singapore, Singapore
|
|
|
|
|
|
|
|
|
|
|
Johns Hopkins Medicine – Baltimore, Maryland, United States
|
|
|
|
|
|
|
Oslo University Hospital – Oslo, Norway
|
|
|
|
|
|
|
The University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
Fred Hutch Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|